跳至主要内容
临床试验/NCT02540707
NCT02540707已完成4 期

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 113 人开始时间: 2015年9月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
113
试验地点
1
主要终点
Between-group difference of the effect of drug on heart rate variability

研究概览

简要总结

Background/Purpose: The overactive bladder syndrome (OAB) affects around 17 % of female population. Antimuscarinics can affect autonomic system, arterial stiffness and psychosomatic distress. However, there is no such research for the new drug- mirabegron (a β3-agonist). Thus, the aim of our study is to analyze the between-group differences in heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, psychosomatic distress, personality trait, family support and clinical outcomes between the mirabegron and the solifenacin groups.

Patients and Methods: The investigators will perform a prospective randomized controlled study to recruit 150 female OAB patients at the outpatient clinic of Department of Obstetrics and Gynecology of National Taiwan University Hospital. All OAB female patients will be asked to complete Urgency Severity Scales, Overactive Bladder Symptoms Scores questionnaires, King's Health questionnaires, UDI-6 & IIQ-7, Patient Health Questionnaire, brief symptom rating scale (BSRS), Maudsley personality inventory (MPI) and adaptability, partnership, growth, affection, and resolve (APGAR) questionnaires, Sleep and Dietary habit Questionnaire, standard 12-leads electrocardiography (ECG), 5 minutes Holter monitoring, cardio-ankle vascular index (CAVI) test, bladder diary, 20-min pad test, urodynamic studies and measurement of urinary nerve growth factors level before and after 12 weeks' mirabegron versus solifenacin treatment. STATA software is used for statistical analyses.

Possible Results: The investigators can answer that the between-group differences in heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, psychosomatic distress, personality trait, family support and clinical outcomes between the mirabegron and the solifenacin groups. The above conclusions should be important for pre-treatment consultation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 99 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women with overactive bladder syndrome
  • ≥20 year-old

排除标准

  • Urine retention,
  • acute angle glaucoma,
  • myasthenia gravis,
  • ulcerative colitis,
  • megacolon

研究组 & 干预措施

Solifenacin

Placebo Comparator

Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks

干预措施: solifenacin (Drug)

Mirabegron

Experimental

Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks

干预措施: mirabegron (Drug)

结局指标

主要结局

Between-group difference of the effect of drug on heart rate variability

时间窗: 12 weeks

Between-group difference of the effect of drug on heart rate variability, such as low frequency and high frequency

Between-group difference of the effect of drug on psychosomatic distress

时间窗: 12 weeks

Between-group difference of the effect of drug on psychosomatic distress by Brief Symptom Rating Scale

次要结局

  • Between-group difference of the effect of drug on arterial stiffness(12 weeks)
  • Between-group difference of the effect of drug on clinical efficacy(12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验